Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.4
4.2
Journals
Molecules
Special Issues
Recent Advances in Techniques with Radionuclide for Theranostic Drugs
molecules-logo
Submit to Molecules Review for Molecules Propose a Special Issue

Journal Menu

► Journal Menu

Journal Browser

► Journal Browser
share announcement

Recent Advances in Techniques with Radionuclide for Theranostic Drugs

A special issue of Molecules (ISSN 1420-3049). This special issue belongs to the section "Photochemistry".

Deadline for manuscript submissions: closed (15 December 2021) | Viewed by 21573

Special Issue Editors

Prof. Dr. Kazuma Ogawa

E-Mail Website1 Website2
Guest Editor
Discovering Molecular Probes Research Unit, Innovative Integrated Bio-Research Core, Institute for Frontier Science Initiative, Kanazawa University, Kakuma-machi, Kanazawa 920-1192, Japan
Interests: theranostics; radiolabeling; radiopharmaceuticals; molecular imaging; cancer; radionuclide therapy; radiosynthesis
Dr. Shigeki Watanabe

E-Mail Website
Guest Editor
Department of Radiation-Applied Biology, Takasaki Advanced Radiation Research Institute, National Institutes for Quantum and Radiological Science and Technology (QST), Watanuki-machi, Takasaki, Gunma 370-1292, Japan
Interests: radionuclide production; radionuclide separation; radiolabeling; radiochemistry; molecular imaging; radionuclide therapy
Dr. Ryuichi Nishii

E-Mail Website
Guest Editor
Department of Molecular Imaging and Theranostics, National Institute of Radiological Sciences (NIRS), National Institutes for Quantum and Radiological Science and Technology (QST), 4-9-1 Anagawa, Inage-ku, Chiba-shi, Chiba 263-8555, Japan
Interests: clinical nuclear medicine; diagnostic imaging; radionuclide therapy; molecular imaging; radiation dosimetry; translational imaging research

Special Issue Information

Dear Colleagues,

In recent years, theranostics (a word coined from “therapeutics” and “diagnostics”) have attracted much attention in oncology. A typical theranostic system has an imaging component for investigating a lesion site before treatment and a corresponding therapeutic one. Because the diagnosis makes the selection of suitable treatment and dose adjustment for each patient possible, theranostics can contribute to the realization of personalized medicine. Theranostics combined with a diagnostic and a therapeutic radionuclide is called “radiotheranostics.” This Special Issue will focus on the synthesis and/or evaluation of radiolabeled compounds containing dosimetry for their clinical application, radionuclide production and separation, and combination of a radionuclide with other modalities for not only radiotheranostics but also imaging as companion diagnosis.

You are cordially invited to contribute to this Special Issue “Recent Advances in Techniques with Radionuclide for Theranostic Drugs” with original articles, as well as reviews and short communications. Areas of interest include, but are not limited to the following Keywords.

Dr. Kazuma Ogawa
Dr. Shigeki Watanabe
Dr. Ryuichi Nishii
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Molecules is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • Synthesis and evaluation of radiolabeled compounds for radiotheranostics
  • Synthesis and evaluation of radiolabeled compounds for imaging as companion diagnosis
  • Techniques using radiolabeled compounds for drug development
  • Production and separation of radionuclides for nuclear medicine
  • Combination of radionuclides (radiolabeled compounds) with other modalities
  • Pharmacokinetics, biodistributiion, and dosimetry for development of radiotheranostics

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (5 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Review

11 pages, 827 KiB  
Article
Positron Emission Intensity in the Decay of 86gY for Use in Dosimetry Studies
by M. Shuza Uddin, Syed M. Qaim, Bernhard Scholten, M. Shamsuzzoha Basunia, Lee A. Bernstein, Ingo Spahn and Bernd Neumaier
Molecules 2022, 27(3), 768; https://doi.org/10.3390/molecules27030768 - 25 Jan 2022
Cited by 6 | Viewed by 2861
Abstract
The β+-emitting radionuclide 86gY (t1/2 = 14.7 h) forms a matched-pair with the β−-emitting therapeutic radionuclide 90Y (t1/2 = 2.7 d) for theranostic application in medicine. This approach demands a precise knowledge of the positron [...] Read more.
The β+-emitting radionuclide 86gY (t1/2 = 14.7 h) forms a matched-pair with the β−-emitting therapeutic radionuclide 90Y (t1/2 = 2.7 d) for theranostic application in medicine. This approach demands a precise knowledge of the positron emission probability of the PET nuclide which was until recently rather uncertain for 86gY. In this work, an 86gY source of high radionuclidic purity was prepared and a direct measurement of the positron emission intensity per 100 decay of the parent (hereafter “positron emission intensity”) was performed using high-resolution HPGe detector γ-ray spectroscopy. The electron capture intensity was also determined as an additional check by measuring the Kα and Kβ X-rays of energies 14.1 and 15.8 keV, respectively, using a low energy HPGe detector. From those measurements, normalized values of 27.2 ± 2.0% for β+-emission and 72.8 ± 2.0% for EC were obtained. These results are in excellent agreement with values recently reported in the literature based on a detailed decay scheme study. Full article
(This article belongs to the Special Issue Recent Advances in Techniques with Radionuclide for Theranostic Drugs)
►▼ Show Figures

Figure 1

14 pages, 1976 KiB  
Article
Re-Evaluations of Zr-DFO Complex Coordination Chemistry for the Estimation of Radiochemical Yields and Chelator-to-Antibody Ratios of 89Zr Immune-PET Tracers
by Ryota Imura, Hiroyuki Ida, Ichiro Sasaki, Noriko S. Ishioka and Shigeki Watanabe
Molecules 2021, 26(16), 4977; https://doi.org/10.3390/molecules26164977 - 17 Aug 2021
Cited by 13 | Viewed by 4998
Abstract
(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (89Zr) to monoclonal antibody (mAb). Despite the remarkable developments of the clinical 89Zr-immuno-PET, chemical species and stability constants of the Zr-DFO complexes remain controversial. The [...] Read more.
(1) Background: Deferoxamine B (DFO) is the most widely used chelator for labeling of zirconium-89 (89Zr) to monoclonal antibody (mAb). Despite the remarkable developments of the clinical 89Zr-immuno-PET, chemical species and stability constants of the Zr-DFO complexes remain controversial. The aim of this study was to re-evaluate their stability constants by identifying species of Zr-DFO complexes and demonstrate that the stability constants can estimate radiochemical yield (RCY) and chelator-to-antibody ratio (CAR). (2) Methods: Zr-DFO species were determined by UV and ESI-MS spectroscopy. Stability constants and speciation of the Zr-DFO complex were redetermined by potentiometric titration. Complexation inhibition of Zr-DFO by residual impurities was investigated by competition titration. (3) Results: Unknown species, ZrHqDFO2, were successfully detected by nano-ESI-Q-MS analysis. We revealed that a dominant specie under radiolabeling condition (pH 7) was ZrHDFO, and its stability constant (logβ111) was 49.1 ± 0.3. Competition titration revealed that residual oxalate inhibits Zr-DFO complex formation. RCYs in different oxalate concentration (0.1 and 0.04 mol/L) were estimated to be 86% and >99%, which was in good agreement with reported results (87%, 97%). (4) Conclusion: This study succeeded in obtaining accurate stability constants of Zr-DFO complexes and estimating RCY and CAR from accurate stability constants established in this study. Full article
(This article belongs to the Special Issue Recent Advances in Techniques with Radionuclide for Theranostic Drugs)
►▼ Show Figures

Figure 1

13 pages, 877 KiB  
Article
Development of Radiogallium-Labeled Peptides for Platelet-Derived Growth Factor Receptor β (PDGFRβ) Imaging: Influence of Different Linkers
by Nurmaya Effendi, Kenji Mishiro, Kazuhiro Shiba, Seigo Kinuya and Kazuma Ogawa
Molecules 2021, 26(1), 41; https://doi.org/10.3390/molecules26010041 - 23 Dec 2020
Cited by 15 | Viewed by 3204
Abstract
The purpose of this study is to develop peptide-based platelet-derived growth factor receptor β (PDGFRβ) imaging probes and examine the effects of several linkers, namely un-natural amino acids (D-alanine and β-alanine) and ethylene-glycol (EG), on the properties of Ga-DOTA-(linker)-IPLPPPRRPFFK peptides. [...] Read more.
The purpose of this study is to develop peptide-based platelet-derived growth factor receptor β (PDGFRβ) imaging probes and examine the effects of several linkers, namely un-natural amino acids (D-alanine and β-alanine) and ethylene-glycol (EG), on the properties of Ga-DOTA-(linker)-IPLPPPRRPFFK peptides. Seven radiotracers, 67Ga-DOTA-(linker)-IPLPPPRRPFFK peptides, were designed, synthesized, and evaluated. The stability and cell uptake in PDGFRβ positive peptide cells were evaluated in vitro. The biodistribution of [67Ga]Ga-DOTA-EG2-IPLPPPRRPFFK ([67Ga]27) and [67Ga]Ga-DOTA-EG4-IPLPPPRRPFFK ([67Ga]28), which were selected based on in vitro stability in murine plasma and cell uptake rates, were determined in BxPC3-luc-bearing nu/nu mice. Seven 67Ga-labeled peptides were successfully synthesized with high radiochemical yields (>85%) and purities (>99%). All evaluated radiotracers were stable in PBS (pH 7.4) at 37 °C. However, only [67Ga]27 and [67Ga]28 remained more than 75% after incubation in murine plasma at 37 °C for 1 h. [67Ga]27 exhibited the highest BxPC3-luc cell uptake among the prepared radiolabeled peptides. As regards the results of the biodistribution experiments, the tumor-to-blood ratios of [67Ga]27 and [67Ga]28 at 1 h post-injection were 2.61 ± 0.75 and 2.05 ± 0.77, respectively. Co-injection of [67Ga]27 and an excess amount of IPLPPPRRPFFK peptide as a blocking agent can significantly decrease this ratio. However, tumor accumulation was not considered sufficient. Therefore, further probe modification is required to assess tumor accumulation for in vivo imaging. Full article
(This article belongs to the Special Issue Recent Advances in Techniques with Radionuclide for Theranostic Drugs)
►▼ Show Figures

Figure 1

14 pages, 2391 KiB  
Article
PARP Theranostic Auger Emitters Are Cytotoxic in BRCA Mutant Ovarian Cancer and Viable Tumors from Ovarian Cancer Patients Enable Ex-Vivo Screening of Tumor Response
by Aladdin Riad, Sarah B. Gitto, Hwan Lee, Harrison D. Winters, Paul M. Martorano, Chia-Ju Hsieh, Kuiying Xu, Dalia K. Omran, Daniel J. Powell, Jr., Robert H. Mach and Mehran Makvandi
Molecules 2020, 25(24), 6029; https://doi.org/10.3390/molecules25246029 - 19 Dec 2020
Cited by 25 | Viewed by 4767
Abstract
Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 [...] Read more.
Theranostics are emerging as a pillar of cancer therapy that enable the use of single molecule constructs for diagnostic and therapeutic application. As poly adenosine diphosphate (ADP)-ribose polymerase 1 (PARP-1) is overexpressed in various cancer types, and is localized to the nucleus, PARP-1 can be safely targeted with Auger emitters to induce DNA damage in tumors. Here, we investigated a radioiodinated PARP inhibitor, [125I]KX1, and show drug target specific DNA damage and subsequent killing of BRCA1 and non-BRCA mutant ovarian cancer cells at sub-pharmacological concentrations several orders of magnitude lower than traditional PARP inhibitors. Furthermore, we demonstrated that viable tumor tissue from ovarian cancer patients can be used to screen tumor radiosensitivity ex-vivo, enabling the direct assessment of therapeutic efficacy. Finally, we showed tumors can be imaged by single-photon computed tomography (SPECT) with PARP theranostic, [123I]KX1, in a human ovarian cancer xenograft mouse model. These data support the utility of PARP-1 targeted radiopharmaceutical therapy as a theranostic option for PARP-1 overexpressing ovarian cancers. Full article
(This article belongs to the Special Issue Recent Advances in Techniques with Radionuclide for Theranostic Drugs)
►▼ Show Figures

Figure 1

Review

Jump to: Research

11 pages, 2013 KiB  
Review
Clinical Perspectives of Theranostics
by Shozo Okamoto, Tohru Shiga and Nagara Tamaki
Molecules 2021, 26(8), 2232; https://doi.org/10.3390/molecules26082232 - 13 Apr 2021
Cited by 28 | Viewed by 4789
Abstract
Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. [...] Read more.
Theranostics is a precision medicine which integrates diagnostic nuclear medicine and radionuclide therapy for various cancers throughout body using suitable tracers and treatment that target specific biological pathways or receptors. This review covers traditional theranostics for thyroid cancer and pheochromocytoma with radioiodine compounds. In addition, recent theranostics of radioimmunotherapy for non-Hodgkin lymphoma, and treatment of bone metastasis using bone seeking radiopharmaceuticals are described. Furthermore, new radiopharmaceuticals for prostatic cancer and pancreatic cancer have been added. Of particular, F-18 Fluoro-2-Deoxyglucose (FDG) Positron Emission Tomography (PET) is often used for treatment monitoring and estimating patient outcome. A recent clinical study highlighted the ability of alpha-radiotherapy with high linear energy transfer (LET) to overcome treatment resistance to beta--particle therapy. Theranostics will become an ever-increasing part of clinical nuclear medicine. Full article
(This article belongs to the Special Issue Recent Advances in Techniques with Radionuclide for Theranostic Drugs)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-5
Back to TopTop